WO2001044455A2 - Antisense oligonucleotides for the inhibition of expression of type i procollagen - Google Patents
Antisense oligonucleotides for the inhibition of expression of type i procollagen Download PDFInfo
- Publication number
- WO2001044455A2 WO2001044455A2 PCT/GB2000/004741 GB0004741W WO0144455A2 WO 2001044455 A2 WO2001044455 A2 WO 2001044455A2 GB 0004741 W GB0004741 W GB 0004741W WO 0144455 A2 WO0144455 A2 WO 0144455A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- nucleotide sequence
- inclusive
- oligonucleotide
- complementary
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ519008A NZ519008A (en) | 1999-12-15 | 2000-12-12 | Antisense oligonucleotides for the inhibition of expression of type I procollagen |
AT00988966T ATE309338T1 (en) | 1999-12-15 | 2000-12-12 | ANTISENSE OLIGONUCLEOTIDES FOR INHIBITION OF EXPRESSION OF TYPE I PROCOLLAGEN |
AU25297/01A AU2529701A (en) | 1999-12-15 | 2000-12-12 | Antisense oligonucleotides |
EP00988966A EP1244781B1 (en) | 1999-12-15 | 2000-12-12 | Antisense oligonucleotides for inhibiting the expression of type i procollagen |
IL14964000A IL149640A0 (en) | 1999-12-15 | 2000-12-12 | Antisense oligonucleotides |
JP2001545532A JP2003516752A (en) | 1999-12-15 | 2000-12-12 | Antisense oligonucleotides for inhibiting the expression of type I procollagen |
DE60023943T DE60023943T2 (en) | 1999-12-15 | 2000-12-12 | ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF THE EXPRESSION OF TYPE I PROCOLLAGEN |
US10/149,352 US7173122B2 (en) | 1999-12-15 | 2000-12-12 | Antisense oligonucleotides to type I procollagen |
KR1020027007591A KR20020064936A (en) | 1999-12-15 | 2000-12-12 | Antisense Oligonucleotides for the Inhibition of Expression of Type I Procollagen |
CA002390674A CA2390674A1 (en) | 1999-12-15 | 2000-12-12 | Antisense oligonucleotides for the inhibition of expression of type i procollagen |
MXPA02005871A MXPA02005871A (en) | 1999-12-15 | 2000-12-12 | Antisense oligonucleotides for the inhibition of expression of type i procollagen. |
BR0016347-3A BR0016347A (en) | 1999-12-15 | 2000-12-12 | Antisense oligonucleotides |
NO20022799A NO20022799L (en) | 1999-12-15 | 2002-06-12 | Antigen oligonucleotides |
US11/021,603 US7396823B2 (en) | 1999-12-15 | 2004-12-21 | Therapy inhalation involving antisense oligonucleotides for treating idiopathic pulmonary fibrosis |
US11/521,843 US8173612B2 (en) | 1999-12-15 | 2006-09-15 | Chemotherapy involving antisense oligonucleotides for preventing and/or treating pulmonary fibrosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9929487.8A GB9929487D0 (en) | 1999-12-15 | 1999-12-15 | Antisense oligonucleotides |
GB9929487.8 | 1999-12-15 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10149352 A-371-Of-International | 2000-12-12 | ||
US11/021,603 Continuation-In-Part US7396823B2 (en) | 1999-12-15 | 2004-12-21 | Therapy inhalation involving antisense oligonucleotides for treating idiopathic pulmonary fibrosis |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001044455A2 true WO2001044455A2 (en) | 2001-06-21 |
WO2001044455A3 WO2001044455A3 (en) | 2002-01-10 |
Family
ID=10866254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2000/004741 WO2001044455A2 (en) | 1999-12-15 | 2000-12-12 | Antisense oligonucleotides for the inhibition of expression of type i procollagen |
Country Status (17)
Country | Link |
---|---|
US (1) | US7173122B2 (en) |
EP (3) | EP2025752A3 (en) |
JP (1) | JP2003516752A (en) |
KR (1) | KR20020064936A (en) |
CN (1) | CN1423695A (en) |
AT (2) | ATE309338T1 (en) |
AU (1) | AU2529701A (en) |
BR (1) | BR0016347A (en) |
CA (1) | CA2390674A1 (en) |
DE (2) | DE60040495D1 (en) |
GB (1) | GB9929487D0 (en) |
IL (1) | IL149640A0 (en) |
MX (1) | MXPA02005871A (en) |
NO (1) | NO20022799L (en) |
NZ (1) | NZ519008A (en) |
WO (1) | WO2001044455A2 (en) |
ZA (1) | ZA200203878B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1838351A2 (en) * | 2004-12-21 | 2007-10-03 | Nath, Rahul Kumar, M.D. | Therapy inhalation involving antisense oligonucleotides for treating idiopathic pulmonary fibrosis |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111378657B (en) * | 2018-12-28 | 2024-03-15 | 苏州瑞博生物技术股份有限公司 | siRNA for inhibiting COL1A1 gene expression, pharmaceutical composition containing siRNA and application thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993011149A1 (en) * | 1991-12-03 | 1993-06-10 | Thomas Jefferson University | Methods of detecting a genetic predisposition for osteoporosis |
WO1994011494A1 (en) * | 1992-11-09 | 1994-05-26 | Thomas Jefferson University | Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen |
WO1994022487A1 (en) * | 1993-03-26 | 1994-10-13 | Thomas Jefferson University | Use of a col 1a1 mini-gene construct to inhibit collagen synthesis |
DE19508923A1 (en) * | 1995-03-13 | 1996-09-19 | Hoechst Ag | New oligo:nucleotide analogues contg. phospho:mono:ester bridges |
WO1998033904A2 (en) * | 1997-01-31 | 1998-08-06 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | An antisense oligonucleotide preparation method |
WO1999049065A1 (en) * | 1998-03-26 | 1999-09-30 | Isis Pharmaceuticals, Inc. | Antisense modulation of human mdm2 expression |
US6007995A (en) * | 1998-06-26 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of TNFR1 expression |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6265157B1 (en) * | 1991-12-03 | 2001-07-24 | Allegheny University Of The Health Sciences | Compositions and methods for detecting altered COL1A1 gene sequences |
EP0739898B1 (en) * | 1995-03-13 | 2001-09-26 | Aventis Pharma Deutschland GmbH | Phosphonomonoester nucleic acids, methods for their preparation and their use |
EP0736608A1 (en) * | 1995-04-08 | 1996-10-09 | Roche Diagnostics GmbH | Method for the specific amplification and the detection of DNA or RNA |
CA2399371A1 (en) * | 1999-11-12 | 2001-05-17 | Fibrogen, Inc. | Animal collagens and gelatins |
-
1999
- 1999-12-15 GB GBGB9929487.8A patent/GB9929487D0/en not_active Ceased
-
2000
- 2000-12-12 DE DE60040495T patent/DE60040495D1/en not_active Expired - Lifetime
- 2000-12-12 EP EP08017586A patent/EP2025752A3/en not_active Withdrawn
- 2000-12-12 EP EP05024183A patent/EP1698695B1/en not_active Expired - Lifetime
- 2000-12-12 NZ NZ519008A patent/NZ519008A/en unknown
- 2000-12-12 JP JP2001545532A patent/JP2003516752A/en active Pending
- 2000-12-12 BR BR0016347-3A patent/BR0016347A/en not_active Application Discontinuation
- 2000-12-12 CN CN00817282A patent/CN1423695A/en active Pending
- 2000-12-12 AU AU25297/01A patent/AU2529701A/en not_active Abandoned
- 2000-12-12 US US10/149,352 patent/US7173122B2/en not_active Expired - Fee Related
- 2000-12-12 DE DE60023943T patent/DE60023943T2/en not_active Expired - Lifetime
- 2000-12-12 WO PCT/GB2000/004741 patent/WO2001044455A2/en active IP Right Grant
- 2000-12-12 AT AT00988966T patent/ATE309338T1/en not_active IP Right Cessation
- 2000-12-12 CA CA002390674A patent/CA2390674A1/en not_active Abandoned
- 2000-12-12 IL IL14964000A patent/IL149640A0/en unknown
- 2000-12-12 MX MXPA02005871A patent/MXPA02005871A/en unknown
- 2000-12-12 AT AT05024183T patent/ATE410510T1/en not_active IP Right Cessation
- 2000-12-12 KR KR1020027007591A patent/KR20020064936A/en not_active Application Discontinuation
- 2000-12-12 EP EP00988966A patent/EP1244781B1/en not_active Expired - Lifetime
-
2002
- 2002-05-15 ZA ZA200203878A patent/ZA200203878B/en unknown
- 2002-06-12 NO NO20022799A patent/NO20022799L/en not_active Application Discontinuation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993011149A1 (en) * | 1991-12-03 | 1993-06-10 | Thomas Jefferson University | Methods of detecting a genetic predisposition for osteoporosis |
WO1994011494A1 (en) * | 1992-11-09 | 1994-05-26 | Thomas Jefferson University | Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen |
WO1994022487A1 (en) * | 1993-03-26 | 1994-10-13 | Thomas Jefferson University | Use of a col 1a1 mini-gene construct to inhibit collagen synthesis |
DE19508923A1 (en) * | 1995-03-13 | 1996-09-19 | Hoechst Ag | New oligo:nucleotide analogues contg. phospho:mono:ester bridges |
WO1998033904A2 (en) * | 1997-01-31 | 1998-08-06 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | An antisense oligonucleotide preparation method |
WO1999049065A1 (en) * | 1998-03-26 | 1999-09-30 | Isis Pharmaceuticals, Inc. | Antisense modulation of human mdm2 expression |
US6007995A (en) * | 1998-06-26 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of TNFR1 expression |
Non-Patent Citations (10)
Title |
---|
ALTMANN K -H ET AL: "NOVEL CHEMISTRY" NEW YORK, WILEY-LISS,US, 1998, pages 73-107, XP002119324 ISBN: 0-471-17279-0 * |
AUSSERLECHNER MICHAEL J ET AL: "Altered procollagen mRNA expression during the progression of avian scleroderma." MOLECULAR MEDICINE (NEW YORK), vol. 3, no. 10, October 1997 (1997-10), pages 654-662, XP000986380 ISSN: 1076-1551 * |
COLIGE A ET AL: "USE OF AN ANTISENSE OLIGONUCLEOTIDE TO INHIBIT EXPRESSION OF A MUTATED HUMAN PROCOLLAGEN GENE (COL1A1) IN TRANSFECTED MOUSE 3T3 CELLS" BIOCHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. EASTON, PA, vol. 32, no. 1, 12 January 1993 (1993-01-12), pages 7-11, XP000652779 ISSN: 0006-2960 * |
HAWKINS J R ET AL: "A 9-BASE PAIR DELETION IN COL1A1 IN A LETHAL VARIANT OF OSTEOGENESIS IMPERFECTA" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 33, 1991, pages 22370-22374, XP000942166 ISSN: 0021-9258 * |
KHILLAN JASPAL S ET AL: "Partial rescue of a lethal phenotype of fragile bones in transgenic mice with a chimeric antisense gene directed against a mutated collagen gene." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 91, no. 14, 1994, pages 6298-6302, XP000942172 1994 ISSN: 0027-8424 * |
LAPTEV ALEXEY V ET AL: "Specific inhibition of expression of a human collagen gene (COL1A1) with modified antisense oligonucleotides. The most effective target sites are clustered in double-stranded regions of the predicted secondary structure for the mRNA." BIOCHEMISTRY, vol. 33, no. 36, 1994, pages 11033-11039, XP000984496 ISSN: 0006-2960 * |
ONODA KEISUKE ET AL: "Role of extracellular matrix in experimental vasospasm: Inhibitory effect of antisense oligonucleotide on collagen induction." STROKE, vol. 27, no. 11, 1996, pages 2102-2108, XP000984053 ISSN: 0039-2499 * |
PROCKOP D J ET AL: "MUTATIONS IN TYPE 1 PROCOLLAGEN THAT CAUSE OSTEOGENESIS IMPERFECTA:EFFECTS OF THE MUTATIONS ON THE ASSEMBLY OF COLLAGEN INTO FIBRILS, THE BASIS OF PHENOTYPIC VARIATIONS, AND POTENTIAL ANTISESE THERAPIES" JOURNAL OF BONE AND MINERAL RESEARCH,US,NEW YORK, NY, vol. 8, no. SUPPL. 02, 1 December 1993 (1993-12-01), pages 489-492, XP000674592 ISSN: 0884-0431 * |
RIRIE SETH S ET AL: "An RNA oligonucleotide corresponding to the polypyrimidine region of the rat alpha1(I) procollagen promoter forms a stable triplex and inhibits transcription." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 249, no. 1, 10 August 1998 (1998-08-10), pages 218-221, XP000942267 ISSN: 0006-291X * |
UHLMANN E ET AL: "ANTISENSE OLIGONUCLEOTIDES: A NEW THERAPEUTIC PRINCIPLE" CHEMICAL REVIEWS,US,AMERICAN CHEMICAL SOCIETY. EASTON, vol. 90, no. 4, 1 June 1990 (1990-06-01), pages 543-584, XP000141412 ISSN: 0009-2665 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1838351A2 (en) * | 2004-12-21 | 2007-10-03 | Nath, Rahul Kumar, M.D. | Therapy inhalation involving antisense oligonucleotides for treating idiopathic pulmonary fibrosis |
WO2006069329A3 (en) * | 2004-12-21 | 2008-10-16 | Nath Rahul K | Therapy inhalation involving antisense oligonucleotides for treating idiopathic pulmonary fibrosis |
EP1838351A4 (en) * | 2004-12-21 | 2010-07-28 | Nath Rahul Kumar M D | Therapy inhalation involving antisense oligonucleotides for treating idiopathic pulmonary fibrosis |
Also Published As
Publication number | Publication date |
---|---|
ATE309338T1 (en) | 2005-11-15 |
AU2529701A (en) | 2001-06-25 |
EP1698695A3 (en) | 2007-02-14 |
NO20022799D0 (en) | 2002-06-12 |
IL149640A0 (en) | 2002-11-10 |
EP1698695A2 (en) | 2006-09-06 |
KR20020064936A (en) | 2002-08-10 |
BR0016347A (en) | 2002-09-10 |
DE60023943D1 (en) | 2005-12-15 |
NO20022799L (en) | 2002-06-12 |
CA2390674A1 (en) | 2001-06-21 |
WO2001044455A3 (en) | 2002-01-10 |
CN1423695A (en) | 2003-06-11 |
ATE410510T1 (en) | 2008-10-15 |
DE60023943T2 (en) | 2006-08-03 |
US7173122B2 (en) | 2007-02-06 |
NZ519008A (en) | 2004-04-30 |
EP2025752A3 (en) | 2009-08-12 |
US20030105050A1 (en) | 2003-06-05 |
EP2025752A2 (en) | 2009-02-18 |
ZA200203878B (en) | 2003-08-15 |
EP1244781A2 (en) | 2002-10-02 |
DE60040495D1 (en) | 2008-11-20 |
EP1698695B1 (en) | 2008-10-08 |
MXPA02005871A (en) | 2002-10-23 |
GB9929487D0 (en) | 2000-02-09 |
EP1244781B1 (en) | 2005-11-09 |
JP2003516752A (en) | 2003-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3054745B2 (en) | Antisense oligonucleotide regulation of raf gene expression | |
US5681747A (en) | Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof | |
US6277832B1 (en) | Growth inhibitor for leukemia cells comprising antisense oligonucleotide derivative to wilms tumor gene (wt1) | |
RU2639550C2 (en) | Treatment of diseases connected with site-1 membrane-impacted peptidase of transcription factors (mbtps1), by inhibiting natural antisense transcript to mbtps1 | |
RU2611187C2 (en) | Treatment diseases, associated with interferon-regulatory factor 8 (irf8), by inhibition of natural antisense transcript to irf8 | |
KR20010102943A (en) | Connective Tissue Growth Factor(CTGF) and Methods of Use | |
WO2000031271A1 (en) | Hiv infection inhibitors | |
JPH10502820A (en) | Oligonucleoside compounds and methods for inhibiting tumor growth, invasion and metastasis | |
EP1838351A2 (en) | Therapy inhalation involving antisense oligonucleotides for treating idiopathic pulmonary fibrosis | |
CA2148687A1 (en) | Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen | |
EP1244781B1 (en) | Antisense oligonucleotides for inhibiting the expression of type i procollagen | |
JPH09104629A (en) | Leukemia cell proliferation inhibiting agent containing antisense oligonucelotide derivative against wilms tumor gene (wt1) | |
AU2009289239A1 (en) | Treatment of scleroderma | |
US5861502A (en) | Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen | |
EP3237619B1 (en) | Compositions and methods for inhibiting expression of adamts-5 and adam17 | |
US5872007A (en) | CAPL-specific oligonucleotides and methods of inhibiting metastatic cancer | |
WO2000017346A2 (en) | Hairpin hybridizer molecules for modulation of gene expression | |
US8173612B2 (en) | Chemotherapy involving antisense oligonucleotides for preventing and/or treating pulmonary fibrosis | |
JP2002512025A (en) | Antisense oligonucleotides for suppression of integrin αv-subunit expression | |
WO1997003681A1 (en) | Methods for selectively killing or inhibiting the growth of cells expressing the waf1 gene | |
WO1999027087A1 (en) | Antisense oligonucleotides specific for cdk4 | |
CN115551519A (en) | Complement component C1S inhibitors for treating neurological diseases and related compositions, systems and methods of using the same | |
MXPA00009974A (en) | ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF INTEGRIN&agr;v | |
MXPA01002953A (en) | Hairpin hybridizer molecules for modulation of gene expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 149640 Country of ref document: IL Ref document number: 25297/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200203878 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 519008 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000988966 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2390674 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10149352 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2001 545532 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/005871 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027007591 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 00817282X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027007591 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000988966 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 519008 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 519008 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000988966 Country of ref document: EP |